ATH 13.7% 4.4¢ alterity therapeutics limited

Brain Cancer Therapeutic Pipeline Review

  1. 1,847 Posts.
    lightbulb Created with Sketch. 1
    Brain Cancer Therapeutic Pipeline Review
    Brain Cancer Therapeutic Pipeline Review H1 2015 Market Research Report at

    Dallas, TX (PRWEB) January 30, 2015

    The report "Brain Cancer – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Brain Cancer. Brain cancer is a tumour or cancerous development in the brain. A main brain tumor starts in the brain. A metastatic brain tumor starts anywhere else in the body and moves to the brain. Almost all tumors that begin in the brain do not spread to other parts of the body. Brain cancer can have a wide range of symptoms including seizures, sleepiness, confusion, nausea and vomiting, behavioral changes and muscle jerking. Brain tumours in children are different from those in adults and are often treated in a different way. Treatment for brain cancer should be individualized for each patient. In most cases of brain cancer surgery, radiation and chemotherapy are the main types of treatment.

    It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. Companies discussed in this Brain Cancer Pipeline Review H1 2015 report include AbbVie Inc., AngioChem Inc., Arrien Pharmaceuticals, LLC, BBB Therapeutics B.V., biOasis Technologies Inc., Bionomics Limited, Bristol-Myers Squibb Company, Cavion LLC, Critical Outcome Technologies Inc., CureFAKtor Pharmaceuticals, LLC, Diffusion Pharmaceuticals LLC, e-Therapeutics plc, Eisai Co., Ltd., Exelixis, Inc., GlaxoSmithKline plc, Hutchison MediPharma Limited, Merrimack Pharmaceuticals, Inc., Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences S.r.l., Neuralstem, Inc., Novartis AG, Oncology Research International Limited, Pfizer Inc., Philogen S.p.A., Phosplatin Therapeutics, Prana Biotechnology Limited, Puma Biotechnology, Inc., RadioRx, Inc., Sagetis Biotech, S.L., Sanofi, Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Takeda Pharmaceutical Company Limited, ThromboGenics NV, Tocagen Inc., Zymeworks Inc.
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Mkt cap ! $43.90M
Open High Low Value Volume
4.6¢ 4.6¢ 4.4¢ $10.3K 225K

Buyers (Bids)

No. Vol. Price($)
1 15000 4.4¢

Sellers (Offers)

Price($) Vol. No.
5.1¢ 120020 2
View Market Depth
Last update - 15.58pm 19/04/2019 (20 minute delay) ?
ATH (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.